This study demonstrates that IDH1R132H mutation with increased oncometabolite R-2HG in PCa cells may play important roles to increase PCa cell invasion.
Massively parallel paired-end sequencing of whole genomes of 10 primary chondrosarcomas revealed that the process of accumulation of somatic mutations is homogeneous irrespective of the pathological subtype or the presence of IDH1 mutations, is unique among a range of cancer types, and shares significant commonalities with that of prostate cancer.
This study suggests that despite the infrequent incidence of the IDH1 mutations in prostate cancers and B-ALL, mutated IDH1 could be therapeutically targeted in these cancers and in glial tumors with the IDH1 mutations.
Overall, our study demonstrates that <i>IDH1</i> expression is associated with prostate cancer progression, that AR signaling integrates one of the first transcriptional mechanisms shown to regulate <i>IDH1</i>, and that AR reprograms prostate cancer cell metabolism by selectively inducing extra-mitochondrial IDH activity.